Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.